Gilead Sciences Inc (GILD.OQ)
23 Mar 2018
Mon, Mar 12 2018
* GILEAD SCIENCES’ NORBERT BISCHOFBERGER, PHD, TO STEP DOWN; JOHN MCHUTCHISON, MD, APPOINTED CHIEF SCIENTIFIC OFFICER AND ANDREW CHENG, MD, PHD, APPOINTED CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:
BRIEF-Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing
* GILEAD SCIENCES INC SAYS IN FEBRUARY 2018, CO RECEIVED NOTICES FROM NATCO PHARMA LIMITED AND TEVA PHARMA - SEC FILING
* APPLICATION TO EXTEND USE OF GILEAD SCIENCES ZYDELIG DRUG FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITHDRAWN Source text for Eikon: (https://goo.gl/D3N4P8) Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)
* GILEAD SCIENCES INC - JAMES MEYERS, EXECUTIVE VICE PRESIDENT, COMMERCIAL OPERATIONS, WILL RETIRE Source text for Eikon: Further company coverage:
U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion (2.16 billion pounds) to Sangamo, the companies said on Thursday.
U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.
* Sangamo stock jumps 21 percent (Adds CEO and executive quotes, background, updates share price)
Feb 22 Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.
BRIEF-Kite, Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For Treatment Of Cancer
* KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER
A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.